Jennifer Rittenberry
Endocrinology, Diabetes & Metabolism · Dublin, OHNPI 1699797688
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,356 of the $141,331 with a category attached, or 78.8%. 32 manufacturers reported payments, led by Novo Nordisk at 41.4% of the total. Reporting peaked in 2019 at $83,973 and has fallen 100.0% since, to $24 in 2024. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 865 payments — averaging $163.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$59K
- Mannkind Corporation$58K
- Tandem Diabetes Care, Inc.$15K
- Valeritas, Inc.$3K
- AbbVie$1K
- Dexcom, Inc.$940
- plus $5K from 26 others
What the payments were for
- Consulting fees$11,9438%
- Speaking & faculty fees$111,35679%
- Travel & lodging$4,6363%
- Food & beverage$13,1449%
- Education$2520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 181 | $58,554 |
| Mannkind Corporation | 207 | $58,170 |
| Tandem Diabetes Care, Inc. | 59 | $14,673 |
| Valeritas, Inc. | 20 | $2,704 |
| AbbVie(2 entities) | 43 | $1,010 |
| Dexcom, Inc. | 27 | $940 |
| Zealand Pharma US, Inc. | 2 | $666 |
| Johnson & Johnson | 25 | $452 |
| Amgen(2 entities) | 24 | $409 |
| Abbott | 13 | $349 |
| Sanofi-aventis U.S. LLC | 24 | $329 |
| Lilly USA, LLC | 43 | $307 |
| AstraZeneca(2 entities) | 14 | $274 |
| Boehringer Ingelheim | 26 | $267 |
| Amarin Pharma, Inc. | 15 | $242 |
| Amneal Pharmaceuticals LLC | 26 | $238 |
| Kowa Pharmaceuticals America, Inc. | 3 | $226 |
| Insulet Corporation | 17 | $203 |
| Merck | 20 | $190 |
| Corcept Therapeutics | 18 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $171 |
| Aegerion Pharmaceuticals, Inc. | 2 | $119 |
| Radius Health, Inc. | 7 | $108 |
| Regeneron Healthcare Solutions, Inc. | 7 | $102 |
| Lifescan, Inc. | 7 | $86 |
| Shire North American Group Inc | 4 | $73 |
| Esperion Therapeutics, Inc. | 1 | $71 |
| Endo Pharmaceuticals Inc. | 5 | $68 |
| Antares Pharma, Inc. | 3 | $59 |
| Pfizer | 3 | $53 |
| IBSA Pharma Inc. | 2 | $25 |
| Companion Medical, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$55,806
- Ozempic$29,020
- Tresiba$11,187
- RYBELSUS$9,979
- t-slim insulin pump$7,910
- t:slim X2 insulin pump$6,500
- Victoza$5,037
- V-GO$3,123
- Creon$348
- Livalo$215
- FreeStyle Lite system$200
- EVENITY$111
- MYALEPT$110
How this compares
$141,331 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Other endocrinology, diabetes & metabolism in Dublin
- Pallavy ReddyDublin$24K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.